Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02616 CSTONE PHARMA-B
RTNominal up7.570 +0.120 (+1.611%)
Others

02/09/2021 09:15

CStone Pharma (02616) gets new drug application accepted

[ET Net News Agency, 2 September 2021] CStone Pharmaceuticals (02616) said the National
Medical Products Administration (NMPA) of China has accepted the new drug application
(NDA) for sugemalimab as a consolidation therapy in patients with unresectable stage III
NSCLC non-small cell lung cancer (NSCLC) without disease progression after concurrent or
sequential chemoradiotherapy. It is the eighth NDA/supplemental NDA submitted by CStone.
Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone.
Authorized by the U.S.-based Ligand Corporation, sugemalimab is developed by the OmniRat
transgenic animal platform, which can generate fully human antibodies in one stop. (RC)

Remark: Real time quote last updated: 14/01/2022 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.